Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Ranked against 17 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NPCE | $422M | — | — | 4.2× | 25.1% | 77.2% | -21.5% | -113% | -27.5% | — | 8 |
| CARL | $408M | — | — | 8.1× | 85.9% | 75.3% | -58.7% | -30.0% | -25.9% | — | 11 |
| SI | $398M | — | — | 8.4× | 49.6% | 76.5% | -85.3% | -28.7% | -25.9% | — | 10 |
| OFIX | $369M | — | — | 0.5× | 2.9% | 68.8% | -11.2% | -20.5% | -15.2% | — | 18 |
| EMBC | $354M | 3.9× | 5.4× | 0.3× | -3.8% | 62.6% | 8.8% | -14.7% | 12.8% | 4.2× | 90 |
| CLPT | $342M | — | — | 9.3× | 17.8% | 61.4% | -69.1% | -91.1% | -33.1% | — | 14 |
| TMCI | $288M | — | — | 1.4× | 1.6% | 79.8% | -27.7% | -67.6% | -40.8% | — | 19 |
| ANIK | $280M | — | — | 2.5× | -5.9% | 56.6% | -9.6% | -7.6% | -7.6% | — | 23 |
| INFU | $280M | 45.4× | 12.2× | 1.9× | 6.4% | 56.0% | 4.6% | 11.6% | 8.6% | 0.7× | 14 |
| OSUR | $272M | — | — | 2.4× | -38.1% | 41.9% | -59.8% | -20.2% | -20.2% | — | 20 |
| PROF | $240M | 4.7× | — | 14.9× | 50.7% | 70.8% | -264% | -64.1% | -60.0% | — | 7 |
| UTMD | $194M | 19.6× | 8.8× | 5.0× | -5.8% | 57.1% | 29.3% | 9.5% | 9.5% | -7.0× | 23 |
| PDEX | $188M | 14.1× | 13.7× | 2.4× | 16.5% | 31.4% | 17.6% | 28.7% | 21.0% | 0.7× | 11 |
| STIM | $171M | — | — | 1.1× | 99.2% | 48.5% | -26.1% | -174% | -44.2% | — | 8 |
| KRMD | $138M | — | — | 3.4× | 22.2% | 62.3% | -6.4% | -15.5% | -15.5% | — | 6 |
| LUNG | $129M | — | — | 1.4× | 8.0% | 74.2% | -59.7% | -99.8% | -59.2% | — | 9 |
| APYX | $110M | — | — | 2.1× | 9.9% | 62.5% | -21.2% | -77.1% | -22.7% | — | 5 |
| USAQ | $5M | 15.0× | 17.4× | 1.7× | 26.3% | 67.3% | -17.0% | -28.1% | -28.1% | -2.9× | — |
Peers = companies sharing USAQ's sector (Surgical & Medical Instruments & Apparatus) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow on any basis, so a reverse DCF can't be run.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M 100.0% | $2.1M 100.0% | $1.4M 100.0% | $1.2M 100.0% | $1.4M 100.0% | $125K 100.0% | — | — | — | — |
| Cost of Revenue | $881K 32.7% | $774K 36.3% | $615K 43.7% | $624K 50.2% | $744K 52.6% | $74K 59.8% | — | — | — | — |
| Gross Profit | $1.8M 67.3% | $1.4M 63.7% | $794K 56.3% | $620K 49.8% | $671K 47.4% | $50K 40.2% | — | — | — | — |
| Research & Development | $485K 18.0% | $294K 13.8% | $214K 15.2% | $190K 15.3% | $91K 6.4% | $98K 78.9% | $100K | — | — | — |
| Selling, General & Admin | $439K 16.3% | $276K 13.0% | $259K 18.4% | $388K 31.2% | $454K 32.1% | $132K 105.8% | $54K | $27K | $105 | $12K |
| Total Operating Expenses | $1.7M 62.4% | $1.2M 54.0% | $1.0M 73.4% | $1.2M 94.9% | $1.2M 82.9% | $325K 261.1% | $154K | $27K | $105 | $23K |
| Operating Income | $131K 4.9% | $206K 9.7% | -$240K -17.0% | -$561K -45.1% | -$502K -35.5% | -$275K -220.9% | -$154K | -$27K | -$105 | -$23K |
| Interest Expense | $237K 8.8% | $465K 21.8% | $230K 16.4% | $433K 34.9% | $246K 17.4% | $31K 24.9% | $12K | $11K | $11K | $11K |
| Pretax Income | $457K 17.0% | -$259K -12.2% | -$468K -33.2% | -$996K -80.1% | -$770K -54.5% | -$327K -262.9% | — | — | — | — |
| Income Tax Expense | — | — | — | $0 0.0% | — | — | — | — | — | — |
| Net Income | -$457K -17.0% | -$259K -12.2% | -$468K -33.2% | -$996K -80.1% | -$770K -54.5% | -$327K -262.9% | -$167K | -$39K | -$11K | -$23K |
| Per Share | ||||||||||
| EPS (Basic) | $0.04 | -$0.03 | -$0.05 | -$0.11 | -$0.10 | — | — | — | — | — |
| EPS (Diluted) | $0.02 | -$0.03 | -$0.05 | -$0.11 | — | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 11.3M | 10.3M | 9.4M | 9.0M | 7.9M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | 19.3M | 10.3M | 9.4M | 9.0M | — | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 13-yr range · 25th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -28% against ROIC -28% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -89.9% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | 59.8 | 52.6 | 50.2 | 43.7 | 36.3 | 32.7 |
| Gross Profit | — | — | 40.2 | 47.4 | 49.8 | 56.3 | 63.7 | 67.3 |
| R&D | — | — | 78.9 | 6.4 | 15.3 | 15.2 | 13.8 | 18.0 |
| SG&A | — | — | 105.8 | 32.1 | 31.2 | 18.4 | 13.0 | 16.3 |
| Operating Income | — | — | -220.9 | -35.5 | -45.1 | -17.0 | 9.7 | 4.9 |
| Income Tax | — | — | — | — | 0.0 | — | — | — |
| Net Income | — | — | -262.9 | -54.5 | -80.1 | -33.2 | -12.2 | -17.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on USAQ: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2020 | 40.2% | -220.9% | -262.9% |
| FY2021 | 47.4% | -35.5% | -54.5% |
| FY2022 | 49.8% | -45.1% | -80.1% |
| FY2023 | 56.3% | -17.0% | -33.2% |
| FY2024 | 63.7% | 9.7% | -12.2% |
| FY2025 | 67.3% | 4.9% | -17.0% |
Return on equity (-28%) and return on invested capital (-28%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
No debt, so there is no leverage path to distress.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
No positive free cash flow to discount, so the price cannot be expressed as a growth requirement.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: free_cash_flow.